Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Open Access
- 19 November 2009
- journal article
- phase i-studies
- Published by Springer Nature in Investigational New Drugs
- Vol. 29 (1) , 137-143
Abstract
Summary Purpose Telatinib is an orally active small-molecule tyrosine kinase inhibitor of kinase insert domain receptor (KDR; VEGFR-2) and fms-related tyrosine kinase 4 (FLT4; VEGFR-3). This study aims at the identification of relationships between single nucleotide polymorphisms (SNPs) in genes encoding for transporter proteins and pharmacokinetic parameters in order to clarify the significant interpatient variability in drug exposure. In addition, the potential relationship between target receptor polymorphisms and toxicity of telatinib is explored. Methods Blood samples from 33 patients enrolled in a phase I dose-escalation study of telatinib were analyzed. For correlation with dose normalized AUC(0–12), ATP-binding cassette (ABC) B1 (ABCB1), ABCC1, and ABCG2 were the genes selected. For correlation with telatinib toxicity, selected genes were the drug target genes KDR and FLT4. Results No association between dose normalized AUC(0–12) and drug transporter protein polymorphisms was observed. In addition, no association between toxicity and KDR or FLT4 genotype or haplotype was seen. Conclusions Our pharmacogenetic analysis could not reveal a correlation between relevant gene polymorphisms and clinical and pharmacokinetic observations of telatinib.Keywords
This publication has 20 references indexed in Scilit:
- Pharmacogenetics in drug discovery and development: a translational perspectiveNature Reviews Drug Discovery, 2008
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesThe American Journal of Human Genetics, 2007
- Translating Pharmacogenomics: Challenges on the Road to the ClinicPLOS Medicine, 2007
- Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid TumorsThe Oncologist, 2007
- Should Pharmacogenomic Studies be Required for New Drug Approval?Clinical Pharmacology & Therapeutics, 2007
- Vascular Endothelial Growth Factor Pharmacogenetics: a New Perspective for Anti-Angiogenic TherapyPharmacogenomics, 2006
- Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2006
- Association of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Gene Polymorphisms with Coronary Artery Lesions of Kawasaki DiseasePediatric Research, 2004
- A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbitalClinical Pharmacology & Therapeutics, 2004
- Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancerBritish Journal of Cancer, 1998